PRMT5 and diffuse large B-cell lymphoma: Finally, drugs targeting the symmetric arginine methyltransferase PRMT5 are also highly active against DLBCL cells, which may be partly related to PRMT5 acting as a corepressor for BCL6.190, 191 As PRMT5 is also involved in RNA‐splicing, the actions of these inhibitors are likely also pleiotropic.